Key Takeaway
Humic acid supplementation reduced intestinal inflammation and improved symptoms in ulcerative colitis patients over 12 weeks.
Summary
This clinical study investigated the effects of oral humic acid supplementation in patients with mild to moderate ulcerative colitis.
Patients received humic acid capsules for 12 weeks while continuing their standard medical therapy. The study assessed clinical symptoms, inflammatory markers, and intestinal mucosal biofilm structure.
Results showed significant improvements in clinical scores and reduced intestinal inflammation, suggesting humic acid may have therapeutic potential as an adjunct therapy for inflammatory bowel conditions.
Methods
- Patients with mild to moderate ulcerative colitis
- 12-week supplementation period
- Humic acid capsules added to standard therapy
- Clinical symptom assessment
- Inflammatory marker measurements
- Intestinal mucosal analysis
Key Results
- Significant improvement in clinical symptom scores
- Reduced intestinal inflammation
- Improved mucosal biofilm structure
- Good tolerability with standard IBD medications
- No significant adverse effects reported
Limitations
- Small sample size
- Open-label design
- No placebo control
- Only studied in ulcerative colitis patients
- Did not assess long-term effects